tislelizumab + cisplatin + gemcitabine + trilaciclib-Mallinckrodt-acute pain

The drug name provided, "tislelizumab + cisplatin + gemcitabine + trilaciclib-Mallinckrodt-acute pain," appears to be a composite entry merging two distinct clinical trial regimens. The first part refers to an oncology combination therapy consisting of **tislelizumab** (a humanized IgG4 monoclonal antibody targeting PD-1), **cisplatin** (a platinum-based chemotherapy), **gemcitabine** (a nucleoside metabolic inhibitor), and **trilaciclib** (a transient CDK4/6 inhibitor used to reduce chemotherapy-induced myelosuppression). This regimen is primarily investigated for advanced solid tumors such as metastatic urothelial cancer (e.g., NCT04863248). The second part, "Mallinckrodt-acute pain," refers to **MNK-155**, an investigational fixed-dose combination of **hydrocodone bitartrate** and **acetaminophen** developed by Mallinckrodt. MNK-155 was studied in Phase 1 trials (e.g., NCT02334475) for the management of moderate to severe acute postsurgical pain in adolescent patients. There is no known clinical use or trial evaluating these five agents as a single combination therapy; the entry likely represents a data error combining an oncology regimen with an analgesic product.

Brand names

Cosela

Other names

hydrocodone bitartrate + acetaminophentislelizumab + cisplatin + gemcitabine + trilaciclib + MNK-155